ID   JHU-LNCaP-SM
AC   CVCL_C0Z9
DR   cancercelllines; CVCL_C0Z9
DR   Wikidata; Q114311775
RX   PubMed=26499105;
RX   PubMed=36261691;
CC   Population: Caucasian.
CC   Characteristics: Androgen-independent. Forms subcutaneous tumors in male athymic nude mice and reliably metastasize to the lymph nodes (PubMed=26499105).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=26499105).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
ST   Source(s): PubMed=26499105
ST   Amelogenin: X
ST   CSF1PO: 9,10,11,12
ST   D13S317: 9,11,12,13
ST   D16S539: 10,11
ST   D5S818: 10,11,12,13
ST   D7S820: 9.1,10.1,10.2,10.3
ST   TH01: 9
ST   TPOX: 9
ST   vWA: 15,16,17,18
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1379 ! LNCaP clone FGC
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=26499105; DOI=10.1002/pros.23115;
RA   Castanares M.A., Copeland B.T., Chowdhury W.H., Liu M.M.,
RA   Rodriguez R., Pomper M.G., Lupold S.E., Foss C.A.;
RT   "Characterization of a novel metastatic prostate cancer cell line of
RT   LNCaP origin.";
RL   Prostate 76:215-225(2016).
//
RX   PubMed=36261691; DOI=10.1038/s41598-022-21593-7;
RA   Mekdad N., Tran T.M.H., Desjardins R., Kwiatkowska A., Couture F.,
RA   Day R.;
RT   "Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model
RT   of androgen independent prostate cancer.";
RL   Sci. Rep. 12:17489-17489(2022).
//